Clinical Trial Update: A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ralinepag effects on exercise capacity in pulmonary arterial hypertension (PAH) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Pulmonary Hypertension

Drugs mentioned

• Ralinepag (ralinepag)

Snippet

Sponsor: United Therapeutics | Conditions: PAH, Pulmonary Hypertension | Phase 3 | Status: TERMINATED